Chronic fatigue syndrome (CFS) is a severe disease characterized by various symptoms of immune dysfunction. CFS onset typically is associated with an infection and many patients suffer from frequently recurrent viral or bacterial infections. Epstein-Barr virus (EBV) has long been discussed as a possible cause or trigger for CFS. To date, there is no marker or single test to confirm a diagnosis of CFS.
The aim of the longtime collaboration with the team of Prof. Scheibenbogen from the Charité (Institute for Medical Immunology) is to distinguish CFS from other disease (e.g. depression) based on the disturbed immune response against EBV. The current project comprises the development of peptide-based assays for this purpose and is funded by the European Union and the program "Investition in Ihre Zukunft".
"Multiple Sclerosis: The Elevated Antibody Response to Epstein-Barr Virus Primarily Targets, but is not Confined to, the Glycine-Alanine Repeat of Epstein-Barr Nuclear Antigen-1"
Ruprecht et al., J. Neuroimmunol. (2014) – PMID: 24798244
"Fine Specificity of the Antibody Response to Epstein-Barr Nuclear Antigen-2 and other Epstein-Barr Virus Proteins in Patients with Clinically Isolated Syndrome: A Peptide Microarray-Based Case-Control Study"
Schlemm et al., J Neuroimmunol. (2016) - PMID: 27397076
"Frequent IgG Subclass and Mannose Binding Lectin Deficiency in Patients with Chronic Fatigue Syndrome"
Guenther et al., Hum Immunol. (2015) – PMID: 26429318
Prof. Scheibenbogen Institute for Medical Immunology, Charité Berlin, Germany
Funded by the European Union and the program “Investition in Ihre Zukunft”.
Partner with us
Contact: Tanja Kaan